ClinicalTrials.gg
CompletedNCT02527265Updated Apr 6, 2021Results posted

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

A Phase 2 interventional study of Afrezza in Type 1 Diabetes Mellitus, sponsored by Mannkind Corporation. Completed at 13 sites in United States. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-04-06.

Sponsored by Mannkind Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
23rd of 35
30 · median 74
Started
2017
with 1 other
Phase 2
8 of 35
1 open now
Registered
29th of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 23rd largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 29th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Primary Objective:

-To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).

Secondary Objectives:

  • To assess the ability to titrate the prandial and supplemental doses of Afrezza at each meal.
  • To assess pharmacokinetics (PK) following a prandial dose of Afrezza in children ages 4 to 17 years with T1DM.
Read the detailed description

The patients are expected to participate in the study for approximately 6 to 8 weeks from Screening to final follow-up visit.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written or oral assent from the pediatric subject and written from the parent(s) or legal guardian and a witness, as required by both state and federal laws and the local Institutional Review Board;
  2. Children aged ≥4 and ≤17 years (enrolled sequentially into 3 age cohorts: 13 to 17, 8 to 12, and 4 to 7 years);
  3. Clinical diagnosis of T1DM and using insulin for at least 1 year;
  4. Currently receiving a regimen of basal/bolus insulin administered by MDI for at least 6 weeks prior to enrollment;
  5. Subjects with pre-breakfast self monitored blood glucose values between 80 and 250 mg/dL for 5 of 7 documented daily readings obtained in the week prior to Visit 2 (readings to be taken using glucometer provided at Screening Visit 1) and reported via the e Diary;
  6. Subjects on a regimen of insulin via continuous SC insulin infusion may be enrolled if they satisfy all other enrollment criteria and are willing to convert to MDI for the duration of the study, beginning 6 weeks prior to enrollment. They must continue to meet all enrollment criteria after converting to the MDI regimen;
  7. Total daily insulin dose ≤1.5 units/kg/day with a minimum of 3 units of RAA at every meal.
  8. (HbA1c) ≥7.0% to \<10.0% at the time of screening;
  9. Fasting serum C-peptide ≤0.3 ng/mL;
  10. (FEV1) ≥70% of National Health and Nutrition Examination Survey (NHANES) III predicted for children ≥8 years of age or Wang predicted for children \<8 years of age;
  11. Forced vital capacity ≥70% of NHANES III predicted for children ≥8 years of age or Wang predicted for children \<8 years of age;
  12. Females of , must use "highly effective" methods of throughout conduct of the trial

Exclusion criteria

Exclusion criteria:

  1. below 25th or above 95th percentile for age and gender according to Centers for Disease Control and Prevention growth charts;
  2. History of physician diagnosis of asthma or any other pulmonary disease, or use of any medications to treat such conditions within the last year;
  3. Allergy or known for AFREZZA or to drugs with similar chemical structure;
  4. Unstable diabetes control, defined as 2 or more episodes of severe hypoglycemia (i.e., an episode associated with a seizure, coma, or loss of consciousness) or any hospitalization or emergency room visit for poor diabetes control, ketoacidosis, hypoglycemia, or hyperglycemia within the preceding 3 months from screening;
  5. Serum creatinine ≥ the for age;
  6. Respiratory tract infection within 30 days before screening or between screening and initiation of treatment period; subject may return 4 weeks after resolution of the infection for rescreening;
  7. Evidence of any complication of diabetes (proliferative retinopathy, autonomic neuropathy, nephropathy, etc), or likelihood of requiring laser photocoagulation, vitrectomy, or other specific treatment for diabetic retinopathy in the coming year;
  8. Smoking of tobacco or other substances or positive urine cotinine testing (>100 ng/mL);
  9. Positive urine drug screen;
  10. Positive urine pregnancy test for female subjects of ;
  11. Inability to perform study procedures including pulmonary function testing;
  12. Exposure to any product(s) in the past 3 months or 5 half-lives, whichever is more;
  13. History of eating disorder;
  14. Any disease or exposure to any medication which, in the judgment of the principal Investigator, may impact glucose metabolism;
  15. Any concurrent medical or major psychiatric condition that makes the subject unsuitable for the clinical study or impairs the subject's ability to participate in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Afrezza (Technosphere Insulin)

    Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days. During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.

    Biological: Afrezza

Interventions

  • BiologicalAfrezza

    Pharmaceutical form: powder Route of administration: inhalation

    Also known as: Technosphere Insulin

06

What researchers measure

Primary outcomes

  1. Insulin Maximum Observed Concentration (Cmax)

    Insulin Cmax after a dose of Afrezza

    Time frame: 250 minutes post-dose

Secondary outcomes

  1. Insulin Time to Reach Cmax (Tmax)

    Insulin Tmax after a dose of Afrezza

    Time frame: 250 minutes post-dose

  2. Insulin Area Under Concentration Time Curve (AUC)

    Insulin AUC after a dose of Afrezza

    Time frame: 250 minutes post-dose

  3. Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2)

    FDKP (inert carrier excipient) calculated half life t1/2

    Time frame: Using PK data collected over 250 minutes post-dose of Afrezza

07

Results

Posted Apr 6, 2021

Participant flow

Participant flow — Overall Study
MilestoneAfrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)
Started1515
Completed1311
Not completed24

Outcome measures

PrimaryInsulin Maximum Observed Concentration (Cmax)

Insulin Cmax after a dose of Afrezza

Time frame:
250 minutes post-dose
Reported as:
Mean · μU/mL
Insulin Maximum Observed Concentration (Cmax)
μU/mLAfrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)
4 unit cartridge28.5 ± 5.77102 ± 31.4
8 unit cartridge101 ± 42.1133 ± 91.0
12 unit cartridge201 ± 118251 ± NA
16 unit cartridge105 ± NA—
SecondaryInsulin Time to Reach Cmax (Tmax)

Insulin Tmax after a dose of Afrezza

Time frame:
250 minutes post-dose
Reported as:
Mean · minutes
Insulin Time to Reach Cmax (Tmax)
minutesAfrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)
4 unit cartridge12.5 ± 3.549.5 ± 4.04
8 unit cartridge13.5 ± 5.4714.1 ± 5.44
12 unit cartridge15.3 ± 3.2710.0 ± NA
16 unit cartridge20.0 ± NA—
SecondaryInsulin Area Under Concentration Time Curve (AUC)

Insulin AUC after a dose of Afrezza

Time frame:
250 minutes post-dose
Reported as:
Mean · min*μU/mL
Insulin Area Under Concentration Time Curve (AUC)
min*μU/mLAfrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)
4 unit cartridge1468 ± 12722931 ± 1011
8 unit cartridge4488 ± 26444975 ± 2921
12 unit cartridge6400 ± 30095971 ± NA
16 unit cartridge5778 ± NA—
SecondaryAssessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2)

FDKP (inert carrier excipient) calculated half life t1/2

Time frame:
Using PK data collected over 250 minutes post-dose of Afrezza
Reported as:
Mean · minutes
Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2)
minutesAfrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)
4 unit cartridge103 ± 23.086.8 ± 6.35
8 unit cartridge123 ± 31.386.5 ± 15.8
12 unit cartridge109 ± 25.995.5 ± NA
16 unit cartridge144 ± NA—

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Afrezza Cohort 1 (Ages 13-17)0/15 (0%)1/15 (6.7%)12/15 (80%)
Afrezza Cohort 2 (Ages 8-12)0/15 (0%)1/15 (6.7%)11/15 (73.3%)
Most frequent serious events
Most frequent serious events
EventAfrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)
Gastroenteritis viralInfections and infestations0/151/15
Diabetic ketoacidosisMetabolism and nutrition disorders1/150/15
Most frequent other events
Showing 10 of 23
Most frequent other events
EventAfrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)
HypoglycemiaMetabolism and nutrition disorders10/1510/15
CoughRespiratory, thoracic and mediastinal disorders7/155/15
Upper respiratory tract infectionInfections and infestations1/153/15
DysmenorrheaReproductive system and breast disorders2/150/15
Throat irritationRespiratory, thoracic and mediastinal disorders1/150/15
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders0/151/15
GastroenteritisInfections and infestations1/150/15
Urinary tract infectionInfections and infestations1/150/15
ConstipationGastrointestinal disorders1/150/15
DiarrhoeaGastrointestinal disorders1/150/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Afrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)Total
Mean15.0 ± 1.7310.4 ± 1.5512.7 ± 2.84
Sex: Female, Male
Sex: Female, Male(Participants)Afrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)Total
Female81018
Male7512
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Afrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)Total
Hispanic or Latino022
Not Hispanic or Latino151328
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Afrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American213
White121325
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)Afrezza Cohort 1 (Ages 13-17)Afrezza Cohort 2 (Ages 8-12)Total
United States151530
08

Study locations

13 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Barbara Davis Center for Childhood Diabetes
    Aurora, Colorado 80045, United States
  • Yale University Hospital
    New Haven, Connecticut 06510, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • USF Diabetes Center
    Tampa, Florida 33612, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Van Meter Pediatric Endocrinology, P.C.
    Atlanta, Georgia 30318, United States
  • Emory University Children's Center
    Atlanta, Georgia 30322, United States
  • Indiana University, Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Barry J. Reiner, MD, LLC
    Baltimore, Maryland 21229, United States
  • Diabetes, Obesity, Cardiovascular Clinical Specialists (DOCS)
    Las Vegas, Nevada 89113, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Mar 2020, 29 months.

Results were first posted in Apr 2021, 1 year after primary completion.

Of 50 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's 29 months is above that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2015
First posted
Aug 18, 2015
StartActual
Sep 28, 2017
Primary completionActual
Mar 17, 2020
CompletionActual
Jun 25, 2020
Results first posted
Apr 6, 2021
Last update
Apr 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02527265
Responsible party
Sponsor
First posted
Aug 18, 2015
Start date
Sep 28, 2017
Primary completion
Mar 17, 2020
Completion
Jun 25, 2020
Results posted
Apr 6, 2021
Last update
Apr 6, 2021

Study contacts

Clinical Operations
study director · Mannkind Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion